HEMOTAG® Assessment for Short-term Outcomes of Heart Failure

Part of paid clinical trials in Weston, Florida.

Sponsor
Aventusoft, LLC.
Study ID
NCT04149743
Status
Recruiting
Apply to this trial

Conditions

  • Heart Failure (HF)

Eligibility Criteria

Sex
ALL
Age
22 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Standard of Care with Hemotag — DIAGNOSTIC_TEST
    Comparison of outcomes

Study Details

Evaluation of the HEMOTAG® system in a less controlled environment and concurrently develop the system for use by patients with heart failure.

Key Dates

Start date
Jan 31, 2022
Status verified
Aug 2024
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024

Study Design

Enrollment
420 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC

Arms

  • No Intervention: Randomized Standard of Care
    Standard of Care
  • Active Comparator: Randomized Standard of Care with HEMOTAG
    Standard of Care with HEMOTAG

Primary Outcome Measure

The number of recurrent HF readmissions. [Monitoring period: 30 days] [ Time Frame: 30 Days ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Cleveland Clinic FloridaWestonFlorida33331
Diana Yanez, BSN,RN
Cecilia Calvo
David Snipelisky (PRINCIPAL_INVESTIGATOR)
Baylor Scott & White Research InstituteTempleTexas76508
Amy M Watts, BSN,RN
Jamie Hernandez-Montfort, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Weston, FL

By research site
Cleveland Clinic Florida· Weston, FLBaylor Scott & White Research Institute· Temple, TX

Related Studies